Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

UBS
Baxter
Boehringer Ingelheim
Mallinckrodt
Merck
Accenture
Fuji
Moodys
Argus Health
Cantor Fitzgerald

Generated: August 22, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title: Methods and compositions for treating pulmonary disorders using optically pure (R,R) formoterol
Abstract:A method and composition are disclosed utilizing the pure (R,R) isomer of formoterol, which is a potent bronchodilator with reduced adverse effects, having a low incidence of the development of tolerance and having increased duration of action.
Inventor(s): Aberg; Gunnar (Westborough, MA), Morley; John (Kew, GB)
Assignee: Sepracor Inc. (Marlborough, MA)
Application Number:09/136,109
Patent Claims: 1. A method of treating asthma, while reducing hypersensitivity, which comprises administering to a human suffering from asthma an amount of (R,R)-formoterol, or a pharmaceutically acceptable salt thereof, sufficient to result in bronchodilation, said (R,R)-formoterol containing at least 99% by weight of (R,R)-formoterol and less than 1% by weight of (S,S)-formoterol.

2. A method of providing relief from bronchospasms, while reducing hypersensitivity, which comprises administering to a human an amount of (R,R)-formoterol, or a pharmaceutically acceptable salt thereof, sufficient to diminish bronchospasms, said (RR)-formoterol containing at least 99% by weight of (R,R)-formoterol and less than 1% by weight of (S,S)-formoterol.

3. The method of claim 2 wherein (R,R) formoterol is administered by subcutaneous injection, intravenous infusion, inhalation, transdermal delivery or oral administration.

4. The method according to claim 3 wherein the amount administered by inhalation is about 1 .mu.g to about 100 .mu.g per day.

5. The method according to claim 3 wherein the amount administered orally is about 0.1 to about 1 mg per day.

6. The method according to claim 2 wherein (R,R) formoterol fumarate dihydrate is administered.

7. The method of claim 1 wherein (R,R) formoterol is administered by subcutaneous injection, intravenous infusion, inhalation, transdermal delivery or oral administration.

8. The method according to claim 7 wherein the amount administered by inhalation is about 1 .mu.g to about 100 .mu.g per day.

9. The method according to claim 7 wherein the amount administered orally is about 0.1 to about 1 mg per day.

10. The method according to claim 1 wherein (R,R) formoterol or pharmaceutically acceptable salt thereof is administered together with a pharmaceutically acceptable carrier.

11. A method according to claim 7 wherein (R,R) formoterol fumarate dehydrate is administered.

12. A method according to claim 8 wherein said amount is administered in divided doses from two to four times a day.

13. A bronchodilator composition in the form of a powder for inhalation which comprises a pharmaceutically acceptable carrier suitable for inhalation and an amount of (R,R)-formoterol, or a pharmaceutically acceptable salt thereof, sufficient to alleviate bronchospasms but insufficient to cause hypersensitivity, said (R,R)-formoterol containing at least 99% by weight of (R,R)-formoterol and less than 1% by weight of (S,S)-formoterol.

14. A composition according to claim 13 adapted for administration by inhalation wherein the amount of (R,R) formoterol is about 6 .mu.g to about 25 .mu.g.

15. A composition according to claim 13 which comprises (R,R) formoterol fumarate dihydrate.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Argus Health
Healthtrust
QuintilesIMS
Accenture
Medtronic
Cipla
Federal Trade Commission
Queensland Health
Daiichi Sankyo
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot